HILLSIDE, N.J., March 29, 2007 (PRIME NEWSWIRE) -- AgroLabs, Inc., a wholly owned subsidiary of Integrated BioPharma, Inc. (Nasdaq:INBP), announced today the introduction of its Naturally Thai Mangosteen liquid dietary supplement at all 171 BJ's Wholesale Club outlets in 16 states.
"We are pleased to work with a retail partner like BJ's to bring another healthy dietary juice supplement to millions of consumers," said Kurt E. Cahill, President and Chief Executive Officer of AgroLabs. Naturally Thai Mangosteen is an addition to Naturally Co-Q Blue, Naturally Noni and Naturally Pomegranate liquid dietary supplements already available at BJ's.
BJ's (NYSE:BJ) was founded in 1984 and is a leading wholesale club chain in the Eastern United States from Maine to Florida and in the state of Ohio.
AgroLabs, Inc. distributes and markets healthful nutritional products under the following brands: Naturally Aloe, Naturally Noni, Naturally Pomegranate, Naturally Thai Mangosteen, Acai Extreme Energy and most recently, Naturally Co-Q Blue, AgroLabs Cranberry Supplement and its Bali Island Trading Company healthful fruit juices. These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. Additional information on AgroLabs and its products can be obtained from its website at www.agrolabs.com or by calling (817) 410-2140.
About Integrated BioPharma Inc.
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.